The dilutive offering at $2.78 (near the current trading level) signals near-term capital needs. Monitor for potential further dilution if ordinary warrants are exercised and for any pipeline updates that could offset the negative sentiment. The lock-up period may limit near-term selling by insiders.
Price Chart
Executive Summary
BioLineRx filed a securities purchase agreement for a registered direct offering of approximately $3,750,000, consisting of 480,696 ADSs at $2.78 per share and pre-funded warrants for up to 868,225 additional ADSs, along with ordinary warrants exercisable at $2.78 for 150% of the placement. The company also amended existing warrants held by Armistice Capital to lower the exercise price to $2.78 and extend the term to 2031. This dilutive financing represents roughly 34% of the current $11M market cap, pressuring existing shareholders.
Key Facts
- Offering size: approximately $3,750,000 in gross proceeds
- Pricing: $2.78 per ADS and $2.7799 per pre-funded warrant
- Securities: 480,696 ADSs + up to 868,225 pre-funded warrant ADSs + ordinary warrants for 150% of placement
- Ordinary warrants: 5-year term, exercise price $2.78
- Lock-up agreements for officers/directors for 60 days post-closing
- Existing warrants held by Armistice Capital amended: exercise price reduced to $2.78, termination extended to August 31, 2031
- Placement agent: Chardan Capital Markets (7% cash fee + 1% management fee)
- Net proceeds for working capital purposes
Financial Impact
Dilution of approximately 34% of current market cap from the offering alone, with additional potential dilution from ordinary warrants (150% of shares placed) and amended Armistice warrants.
Risk Factors
- Significant dilution to existing shareholders from the offering and warrant exercises
- Micro-cap biotech with no disclosed revenue or near-term catalysts in this filing
- Potential overhang from the amended Armistice warrants now exercisable at $2.78
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-004334 |
| Exhibit: exhibit_10-3.htm | 0001178913-26-004334 |
| Exhibit: exhibit_10-2.htm | 0001178913-26-004334 |
| Exhibit: exhibit_10-5.htm | 0001178913-26-004334 |
| Exhibit: exhibit_5-2.htm | 0001178913-26-004334 |
| Exhibit: exhibit_5-1.htm | 0001178913-26-004334 |
| Exhibit: exhibit_10-4.htm | 0001178913-26-004334 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.04 | awaiting T+20 | — | $2.03 (−0.49%) |
Oct 5, 2026 22d ago | EFFECT | $2.32 | awaiting T+20 | — | $2.03 (+12.50%) |
Sep 25, 2026 4w ago | F-1 | $2.43 $2.00 | ▼ −17.70% | ▼ −17.66% | $2.03 (−16.46%) |
Sep 10, 2026 6w ago | 6-K | $2.57 $2.21 | ▼ −13.99% | ▼ −16.12% | $2.03 (−21.00%) |
Aug 31, 2026 8w ago | 424B5 | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 28, 2026 8w ago | 6-K | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.03 (+21.92%) |
Aug 28, 2026 8w ago | Press Release | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.03 (+21.92%) |
Jul 8, 2026 15w ago | 6-K | $3.01 $2.72 | ▼ −9.73% | ▼ −13.01% | $2.03 (−32.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers